Preclinical Assessment of Anti-Tumor Activity and Immune Response in Syngeneic Tumor Models

EORTC-NCI-AACR 2016 -- Preclinical immuno-oncology (I/O) needs identification and refinement of tumor models that recapitulate relevant biological dynamics. We tested several murine models for their response to checkpoint inhibitors like anti-CTLA-4, anti-PD-L1 and anti-PD-1 antibodies and found sensitive, moderately sensitive and insensitive models. Since the application of more sophisticated endpoints is critical to confidently assess drug sensitivities we also evaluated the immune profiles of these models following treatment.